Monoclonal Antibody to Human CD59

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 11; NC_000011.9 (33724556..33758025, complement). Location: 11p13

Monoclonal

IgG2a

MEM-43

Host: Mouse
Source: Culture

CD59
Reacts with well defined epitope (W40, R-53) on CD59 (Protectin), a 19-25 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on all hematopoietic cells. It is widely present on cells in all tissues.

>95% pure (SDS-PAGE). Protein A chromatography

Purified, Liquid

1mg/ml (lot specific)

Short term store at 2 to 8 degree C. Long term, aliquot and store at -20 degree C. Avoid multiple freeze/thaw cycles.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of anti-CD59 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Monoclonal Antibodies to Human CDs

Flow Cytometry, Immunoprecipitation

14,177 Da[Similar Products]

CD59 molecule, complement regulatory protein

CD59 glycoprotein; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; OTTHUMP00000232408; OTTHUMP00000232409; OTTHUMP00000232410; OTTHUMP00000232411; OTTHUMP00000232412; OTTHUMP00000232413; OTTHUMP00000232414; OTTHUMP00000232415; OTTHUMP00000232416; OTTHUMP00000232608; OTTHUMP00000232610; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal antibody 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)

CD59 glycoprotein

MIC11; MIN1; MIN2; MIN3; MSK21??[Similar Products]

CD59_HUMAN

This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq]

Function: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.

Subunit structure: Interacts with T-cell surface antigen CD2. Ref.13

Subcellular location: Cell membrane; Lipid-anchor ? GPI-anchor. Secreted. Note: Soluble form found in a number of tissues. Ref.12 Ref.16 Ref.18 Ref.19 Ref.20

Post-translational modification: N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants. Ref.11 Ref.16 Ref.21Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.

Involvement in disease: Defects in CD59 are the cause of CD59 deficiency (CD59D) [

MIM:612300]. Ref.25

Sequence similarities: Contains 1 UPAR/Ly6 domain.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.